Estrella Immunopharma, Inc.
ESLA
$1.72
$0.148.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -26.62% | 27.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.40% | 163.46% | |||
| Operating Income | 13.40% | -163.46% | |||
| Income Before Tax | 13.40% | -163.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.41% | -163.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.41% | -163.50% | |||
| EBIT | 13.40% | -163.46% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 15.59% | -163.86% | |||
| Normalized Basic EPS | 15.55% | -163.91% | |||
| EPS Diluted | 15.59% | -163.86% | |||
| Normalized Diluted EPS | 15.55% | -163.91% | |||
| Average Basic Shares Outstanding | 2.57% | -0.06% | |||
| Average Diluted Shares Outstanding | 2.57% | -0.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||